O'Connor Margaret H, Rhodin Kristen E, Tyler Douglas S, Beasley Georgia M
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Department of Surgery, Texas Medical Branch, Galveston, TX, USA.
Surg Oncol Clin N Am. 2025 Jul;34(3):393-410. doi: 10.1016/j.soc.2024.11.004. Epub 2024 Dec 6.
In-transit (IT) melanoma represents a distinct, heterogeneous pattern of disease that arises as superficial tumors along the track between the primary site and the draining regional lymph node basin. Many therapies have been explored for treatment of this disease with the goal of maximizing delivery of the therapeutic agent to the tumor while minimizing systemic toxicities. These include regional chemotherapies, intralesional injections, checkpoint inhibitors, immunomodulators, and vaccines in various combinations or as monotherapy. Here, we review the general managemnt of patients with ITmelanoma, the range of currently available treatment options, and recommendations for specific therapies for individual patients.
移行性（IT）黑色素瘤代表一种独特的、异质性的疾病模式，它表现为沿原发部位与引流区域淋巴结区域之间路径的浅表肿瘤。人们已经探索了许多治疗这种疾病的方法，目标是在使全身毒性最小化的同时，将治疗药物最大限度地输送到肿瘤部位。这些方法包括区域化疗、瘤内注射、检查点抑制剂、免疫调节剂和疫苗，它们可以各种组合使用或作为单一疗法。在这里，我们回顾了IT黑色素瘤患者的一般管理、当前可用的治疗选择范围，以及针对个体患者的特定治疗建议。
